Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Home
Protagonist Therapeutics Inc
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
Business
Dec 9 2024
5 min read

Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting

54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (5/year:

  • In Part 1, the EPHL was